Search
                    Hidradenitis Suppurativa (HS) Clinical Trials
A listing of 5  Hidradenitis Suppurativa (HS)  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 5 of 5
        
        
    
                There are currently 5 active clinical trials seeking participants for Hidradenitis Suppurativa (HS) research studies. The states with the highest number of trials for Hidradenitis Suppurativa (HS) participants are Florida, Ontario, California and Texas.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Investigative Site US303, Phoenix, Arizona  +171 locations         
        
        
            Conditions: Hidradenitis Suppurativa (HS)
        
            
        
    
                
                                    Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
                                
            
            
        Recruiting
                            
            
                Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Investigative Site US086, Birmingham, Alabama  +342 locations         
        
        
            Conditions: Hidradenitis Suppurativa (HS)
        
            
        
    
                
                                    Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
                                
            
            
        Recruiting
                            
            
                The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                08/14/2025
            
            Locations: Wallace Medical Group, Inc., Los Angeles, California  +24 locations         
        
        
            Conditions: Hidradenitis Suppurativa (HS)
        
            
        
    
                
                                    A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
                                
            
            
        Recruiting
                            
            
                To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 71 years
            Trial Updated:
                08/07/2025
            
            Locations: UCSF Medical Center, San Francisco, California  +9 locations         
        
        
            Conditions: Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
        
            
        
    
                
                                    Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to learn if drug EVO101 works to treat mild to moderate hidradenitis suppurativa in adults. The main questions it aims to answer are:
Does drug EVO101 lower the total number of lesion a participant has from the first visit to the last visit.
What medical problems do participants have when applying drug EVO101 Does a participant perceive a change in their hidradenitis suppurativa symptoms based on patient reported outcome questionnaires.
Participants will:
A...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                12/05/2024
            
            Locations: Virginia Clinical Research, Inc., Norfolk, Virginia         
        
        
            Conditions: Hidradenitis Suppurativa (HS)
        
            
        
    1 - 5 of 5
            
            
        